Oruka Therapeutics (ORKA) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental analysis rates ORKA as Neutral with a low 3.3/10 score. Profit‑MV and Cash‑MV are positive, while Asset‑MV and Revenue‑MV lag. Inventory turnover is strong, but gross margin and tax ratios are modest, indicating selective investment appeal.

Analysis Checks(7/10)

Revenue-MV

Value-0.08

Score1/3

Weight16.03%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight19.45%

1M Return6.65%

Gross profit margin (%)

Value48.34

Score1/3

Weight0.76%

1M Return0.36%

Profit-MV

Value0.68

Score2/3

Weight18.30%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score2/3

Weight2.30%

1M Return0.98%

Current assets turnover ratio

Value2.44

Score2/3

Weight4.20%

1M Return1.91%

Fixed assets turnover ratio

Value9771.06

Score3/3

Weight3.88%

1M Return1.76%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight9.67%

1M Return4.08%

Asset-MV

Value-0.55

Score0/3

Weight7.51%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight17.92%

1M Return6.19%

Is ORKA undervalued or overvalued?

ORKA scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -24.69% ROE, 0.00% net margin, -21.36 P/E ratio, 4.77 P/B ratio, and 52.20% earnings growth, these metrics solidify its Netural investment rating.